Scarica l'app Stockscreener
25.64
1.72%
-0.45
Dopo l'orario di chiusura:
25.64
Precedente Chiudi:
$26.09
Aprire:
$25.88
Volume 24 ore:
697.74K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.27B
Reddito:
-
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-12.45
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
-6.25%
1M Prestazione:
-6.01%
6M Prestazione:
-7.10%
1 anno Prestazione:
+81.46%
Intervallo 1D:
$25.42
$25.89
Intervallo di 1 settimana:
$25.10
$28.09
Portata 52W:
$14.16
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
25.64 | 2.39B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE - marketbeat.com
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell" - marketbeat.com
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen - marketbeat.com
Q3 EPS Estimate for Mineralys Therapeutics Raised by Analyst - marketbeat.com
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares - Stock Titan
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards - Stock Titan
What is HC Wainwright's Estimate for MLYS FY2030 Earnings? - marketbeat.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55 - moomoo.com
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback - webull.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock - Investing.com
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock - marketbeat.com
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan - Stock Titan
BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $49 - moomoo.com
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Earnings Miss - marketbeat.com
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside - TradingView
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.75, Implies 78% Upside - TradingView
Transcript : Mineralys Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Mineralys Q2 Results: Net Loss Widens To $241.1 Million - scanx.trade
Mineralys Therapeutics Q2 Earnings Call Highlights - MarketBeat
MLYS: Q2 2026 featured robust launch preparations, strategic capital moves, and strong lorundrostat data - TradingView
Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results - marketbeat.com
Earnings call transcript: Mineralys Q2 2026 loss widens, shares fall after hours - Investing.com
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing - Stock Traders Daily
Why is Mineralys Therapeutics stock sliding today? - Investing.com
Why is Mineralys Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest - Stock Titan
Mineralys Therapeutics Q2 Loss Widens - marketscreener.com
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss - marketscreener.com
Mineralys Therapeutics earnings up next as losses expected to widen By Investing.com - Investing.com UK
Mineralys Therapeutics Appoints James J. Ferguson III as New Chief Medical Officer and Reports Q2 2026 Financial Results - Kalkine Media
Mineralys Therapeutics falls 8% on second quarter EPS miss By Investing.com - Investing.com Australia
Mineralys Therapeutics falls 8% on second quarter EPS miss - Investing.com India
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Mineralys' Blood-Pressure Candidate Has Dec. 22 FDA Target Date - Stock Titan
Mineralys Therapeutics earnings up next as losses expected to widen - Investing.com
Janus Henderson Group PLC Has $537,000 Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - marketbeat.com
Mineralys Therapeutics (MLYS) – David Rodman files Rule 144 for stock sale - Stock Titan
FMR LLC reports 5.1% Mineralys Therapeutics (MLYS) stake in amended ownership filing - Stock Titan
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View - Yahoo Finance
Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Tuesday - MarketBeat
Mineralys Therapeutics to Report Second Quarter 2026 Financial Results on August 11 - Quiver Quantitative
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 - The Manila Times
Mineralys Therapeutics to Announce Second Quarter 2026 - GlobeNewswire
Mineralys schedules live webcast for Aug. 11 Q2 update - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):